One of the most common questions parents ask when exploring growth treatment options is whether it is better to address growth concerns before puberty begins.
The answer is often yes.
The years before puberty represent one of the most important windows for growth and development. During this stage, growth plates remain open, growth hormone signaling is highly active, and children still have significant height potential remaining.
Because puberty eventually leads to growth plate closure, many pediatric growth specialists emphasize early evaluation when concerns arise.
For some children, therapies that support natural growth hormone signaling may be considered during this period. One example is Sermorelin for children, a therapy designed to stimulate the body's own production of growth hormone rather than replacing it directly.
Understanding why timing matters can help parents make informed decisions about their child's growth and future height potential.
Why the Years Before Puberty Are So Important
Children do not grow at the same rate throughout childhood.
Growth occurs in distinct phases:
Infancy
Rapid growth occurs during the first few years of life.
Childhood
Growth becomes more steady and predictable.
Puberty
A major growth spurt typically occurs before growth plates begin closing.
The years leading up to puberty are particularly important because the body is preparing for its largest period of height gain.
During this stage:
- Growth plates remain open
- Skeletal development is ongoing
- Hormone responsiveness is high
- Growth hormone signaling remains active
- Significant growth potential remains available
When growth concerns are identified early, there is often more opportunity to investigate potential causes and support healthy development.
Understanding Growth Plates and Height Potential
Growth occurs at specialized areas of cartilage known as growth plates.
These growth plates are located near the ends of long bones and allow bones to lengthen throughout childhood and adolescence.
As puberty progresses, growth plates gradually mature and eventually fuse.
Once growth plates close, meaningful height increases become extremely limited.
This is one reason providers often encourage families to investigate concerns such as:
before skeletal maturation is complete.
The earlier concerns are identified, the greater the opportunity to maximize remaining growth potential.
How Growth Hormone Influences Height
Growth hormone plays a central role in childhood growth.
The normal growth pathway involves several steps.
Step 1: The Brain Releases GHRH
The hypothalamus produces Growth Hormone Releasing Hormone (GHRH).
Step 2: The Pituitary Gland Releases Growth Hormone
GHRH signals the pituitary gland to release growth hormone.
Step 3: The Liver Produces IGF-1
Growth hormone stimulates the production of Insulin-Like Growth Factor-1 (IGF-1).
Step 4: Growth Plates Respond
IGF-1 stimulates cartilage cells within growth plates, allowing bones to lengthen over time.
Disruptions anywhere within this pathway may affect growth velocity and final adult height.
What Is Sermorelin?
Sermorelin is a synthetic version of Growth Hormone Releasing Hormone (GHRH).
Rather than replacing growth hormone directly, Sermorelin encourages the body's natural production of growth hormone through stimulation of the pituitary gland.
This means the body remains actively involved in regulating hormone release.
Many parents researching does Sermorelin help kids grow taller are attracted to this physiologic approach because it supports the body's normal growth pathways.
Why Timing Matters with Sermorelin Therapy
One of the most important concepts in pediatric growth medicine is that growth opportunity decreases with time.
A child who is 8 years old generally has significantly more growth potential remaining than a child who is 15 years old.
This does not automatically mean treatment is appropriate, but it does mean evaluation becomes increasingly important as children approach puberty.
When growth signaling is optimized while growth plates remain open, children have more time available to respond.
This is why early assessment is often recommended for children experiencing:
- Slow growth
- Short stature
- Delayed developmental timing
- Predicted adult height below family expectations
Waiting until growth plates begin closing may reduce available options.
Potential Benefits of Addressing Growth Concerns Before Puberty
When growth concerns are identified and evaluated early, several potential advantages exist.
More Remaining Growth Potential
Children who have not yet entered puberty typically have more years of growth remaining.
Open Growth Plates
Growth plates are generally more responsive before advanced skeletal maturation occurs.
Improved Growth Monitoring
Early evaluation provides more time to track growth trends and identify changes.
Better Understanding of Growth Patterns
Providers can distinguish between conditions such as:
- idiopathic short stature
- constitutional growth delay
- growth hormone deficiency
- pituitary disorders
This helps families make informed decisions regarding future care.
Which Children May Be Evaluated for Growth Concerns?
A pediatric growth evaluation may be appropriate when a child:
- Falls below expected height percentiles
- Demonstrates poor growth velocity
- Appears significantly shorter than peers
- Shows delayed pubertal development
- Has a family history of growth disorders
- Has declining growth chart trends
Parents often seek answers after wondering:
These concerns are often appropriate reasons to pursue evaluation.
The Role of Bone Age Testing
One of the most important tools used during growth assessment is a bone age test.
Bone age evaluates skeletal maturity using an X-ray of the hand and wrist.
This information helps determine:
- Remaining growth potential
- Growth plate status
- Predicted adult height
- Developmental timing
Children with delayed skeletal maturation frequently have more growth opportunity remaining.
This is one reason delayed bone age can significantly influence treatment decisions.
Why IGF-1 Levels Matter
Growth hormone does not directly cause bones to lengthen.
Instead, much of its effect occurs through IGF-1.
Children with low IGF-1 levels may demonstrate reduced growth signaling despite appearing otherwise healthy.
Evaluating IGF-1 is often an important part of pediatric growth assessment.
Combined with growth charts, bone age, and growth velocity, IGF-1 testing helps providers better understand the growth pathway.
What Parents May Notice During Growth Improvement
Growth occurs gradually.
Parents should not expect dramatic overnight changes.
Instead, improvements typically develop over months and years.
Some families report:
Improved Growth Velocity
Children may begin gaining height at a faster annual rate.
Better Growth Chart Progression
Movement upward on growth charts may occur gradually.
Improved Sleep Patterns
Growth hormone release is closely linked to sleep quality.
Increased Appetite
Some children experience increased nutritional demands as growth accelerates.
Improved Confidence
As growth improves, children sometimes feel more confident socially and athletically.
Why Not Every Child Needs Treatment
One of the most important points parents should understand is that short stature does not automatically require treatment.
Many children grow differently than peers but ultimately reach healthy adult heights.
Children with constitutional growth delay often mature later than classmates and continue growing longer.
Some children simply require monitoring rather than intervention.
The goal of evaluation is determining whether growth is occurring normally, not automatically prescribing treatment.
Why Early Evaluation Provides More Options
One of the greatest benefits of early assessment is preserving opportunity.
Children who undergo evaluation before puberty often have:
- More growth potential remaining
- More time available for monitoring
- Better ability to identify underlying causes
- Greater flexibility regarding treatment decisions
By contrast, children evaluated late in puberty may have fewer options because skeletal maturation is already nearing completion.
This is why parents should pay attention to the signs your child may need growth hormone testing rather than waiting years to investigate concerns.
Frequently Asked Questions
Is it better to evaluate growth concerns before puberty?
In most cases, yes. Earlier evaluation provides more time to understand growth patterns and identify potential causes of short stature.
Can a child still grow after puberty begins?
Yes. Growth continues during puberty, but growth potential gradually decreases as growth plates mature.
Does every child with short stature need treatment?
No. Many children simply require monitoring and reassurance.
Can delayed puberty affect height?
Yes. Children with delayed puberty often appear significantly shorter than peers for a period of time.
What if my child is growing less than expected?
Children who are growing less than 2 inches per year may benefit from further evaluation.
The Bottom Line
The years before puberty represent one of the most important windows for childhood growth.
Growth plates remain open, hormone signaling remains active, and significant height potential is still available.
For children experiencing poor growth velocity, delayed bone age, low IGF-1 levels, short stature, or delayed development, early evaluation may help identify opportunities to support healthy growth while growth potential remains.
When appropriate, Sermorelin for children may be considered as part of a comprehensive approach to supporting natural growth hormone production and healthy growth signaling.
The goal is never to rush development. The goal is to understand a child's growth pattern, preserve opportunity, and help maximize healthy growth potential before growth plates eventually close.
Medically Reviewed By
Dr. Devin Stone, ND
Dr. Devin Stone is a Doctor of Naturopathic Medicine and founder of HGHforChildren.com. His clinical focus includes pediatric growth optimization, short stature evaluation, growth hormone signaling, delayed bone age assessment, constitutional growth delay, IGF-1 evaluation, and evidence-informed therapies designed to help children maximize healthy growth potential.
References
Grimberg A, DiVall SA, Polychronakos C, et al. Guidelines for Growth Hormone and IGF-I Treatment in Children. Hormone Research in Paediatrics.
Growth Hormone Research Society. Consensus Guidelines for Pediatric Growth Disorders.
American Academy of Pediatrics. Evaluation and Management of Short Stature in Children.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Growth Disorders and Growth Hormone Deficiency.
National Institutes of Health (NIH). Pediatric Endocrinology and Growth Assessment Resources.
Dr. Devin Stone
Contact Me
